Translarna is applied in situations involving Duchenne Muscular Dystrophy (DMD) linked to a specific nonsense mutation. The therapeutic use is defined by this genetic requirement within a specific patient subgroup. This treatment is indicated for ambulatory patients aged 2 years and older.

The primary focus is managing symptoms related to progressive motor decline and difficulties with walking ability in children and young adults with nmDMD. It is generally used within a chronic care context, where it contributes to easing the overall symptom load associated with disease progression. The primary benefit is assisting with functional stability, which supports independence and comfort when performing routine activities.

Managing Progressive Motor Decline

This intervention is commonly used in ambulatory patients (those who can still walk) to help address symptoms related to progressive motor decline. This supportive relief is relevant when symptoms create noticeable physiological strain.

---

Quick Fact: Supportive Management for Motor Decline	Property	Description
Condition Type	Nonsense Mutation Duchenne Muscular Dystrophy
Symptom Focus	Progressive motor decline, difficulties with walking ability
Primary Benefit	Helps manage functional capabilities
Usage Context	Chronic care framework, alongside standard therapy

This section outlines the official population eligibility and exclusion criteria for Translarna (ataluren) as specified in government regulatory documents.

Official Eligibility Statements

Category	Eligibility Rule
Approved Patient Profile	Ambulatory patients aged 2 years and older with Duchenne Muscular Dystrophy (DMD) resulting from a nonsense mutation in the dystrophin gene. Genetic confirmation of the mutation is required.
Absolute Contraindications	The medicine must not be used by patients with a known hypersensitivity to ataluren or any of the product’s excipients. Concomitant use of intravenous aminoglycosides is also strictly contraindicated.

Populations Requiring Restrictions or Special Consideration

Category	Regulatory Status
Specific Genetic Exclusion	Patients who do not have a nonsense mutation in the dystrophin gene should not receive ataluren.
Non-Ambulatory Status	The medicine is indicated for ambulatory patients; efficacy has not been confirmed in those who have lost the ability to walk.
Severe Renal Impairment	Treatment should not be initiated in previously untreated patients with severe renal impairment (eGFR < 30 mL/min). Continuation of treatment in patients with severe renal impairment or end-stage renal disease is not recommended.
Pregnancy and Lactation	Use during pregnancy is recommended to be avoided. Breastfeeding must be discontinued during treatment.
Use Not Established	Safety and efficacy have not yet been established in children under 2 years of age, patients aged 65 and older, or patients with hepatic impairment.

Connection to the Overall Eligibility Profile

The regulatory documents establish that eligibility for Translarna is fundamentally contingent upon two factors: the presence of the nonsense mutation and the patient's ambulatory status. Exclusions are strictly defined by contraindications (hypersensitivity, certain co-administered drugs) and caution is mandated for specific groups, notably those with severely impaired kidney function and patients who are pregnant or breastfeeding.

Interactions with other medicines and products

Official regulatory documents detail specific interactions that may occur when ataluren is administered alongside other substances, classifying them based on the mechanism and resulting restriction.

Classification	Interacting Substance/Class	Official Interaction Restriction/Outcome
Contraindicated Combination	Intravenous Aminoglycosides	Prohibited for co-administration due to risk of increased nephrotoxicity and potential interference with ataluren activity. If necessary, ataluren treatment must be stopped and resumed 2 days after the aminoglycoside course ends.
Use With Caution	UGT1A9 Inducers (e.g., Rifampicin)	Co-administration may reduce ataluren plasma concentration, requiring caution due to potential decreased exposure.
Use With Caution	OAT1, OAT3, or OATP1B3 Substrates (e.g., Ciprofloxacin, Adefovir, Valsartan, Pravastatin)	Ataluren is documented to increase the exposure (plasma concentrations) of these co-administered medicines, necessitating caution.
Not Recommended	Other Nephrotoxic Medicinal Products (e.g., Vancomycin)	Concomitant use is not recommended; if unavoidable, careful monitoring of renal function is advised due to the risk of additive nephrotoxicity.
Monitoring Required	Systemic Corticosteroids	Co-administration is associated with a risk of hypertension in some patients, and blood pressure monitoring is officially recommended.

Ataluren is an inhibitor of the organic anion transporters OAT1, OAT3, and OATP1B3, which is the documented basis for the increased plasma concentrations of their substrates. The concomitant use of intravenous aminoglycosides is the only formal prohibition documented in the regulatory label. There are no restrictions documented for interactions with food, alcohol, or herbal products in the official interaction section.

Targeted Modulation of Genetic Translation

The compound ataluren acts at the molecular level by targeting the eukaryotic ribosome and Premature Termination Codons (PTCs). It functions as an inhibitor and modulator of the Eukaryotic Release Factor 1 (eRF1) complex, which interferes with the translation termination process. This action promotes the read-through of the stop signal, enabling the synthesis of a full-length polypeptide chain.

Re-establishment of Muscle Cell Infrastructure Component

The consequence of read-through is the re-establishment of the production of essential structural proteins (like dystrophin). The subsequent integration of this full-length protein into the muscle cell is associated with the stabilization of the sarcolemma (muscle cell membrane), thereby altering the chronic structural pathology associated with fiber damage by supporting the maintenance of structural linkage within the muscle cell.

Mechanistic Constraints and Contextual Dependency

The efficiency of the read-through mechanism is highly specific and dependent on the nucleotide context immediately surrounding the PTC. Furthermore, the resulting protein is not the wild-type, as a substituted amino acid is inserted at the mutation site. These intrinsic biological constraints govern the structural consequence and the physiological outcome of the mechanism.

How Translarna (Ataluren) is Used

Translarna is an oral medicine administered as granules for suspension and is used as part of a continuous, long-term treatment plan. The administration follows a precise schedule. Treatment is initiated and overseen by a specialist physician experienced in Duchenne muscular dystrophy.

---

Official Dosing and Administration Protocol

Translarna’s usage is based on a total daily dose of 40 mg/kg body weight. This total amount is always divided into three separate doses taken each day: 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening. This staggered schedule ensures specific concentration levels are achieved throughout the day.

Dosing Frequency	Dosing Interval	Dose Concentration
Morning Dose	12 hours after previous evening dose	10 mg/kg
Midday Dose	6 hours after morning dose	10 mg/kg
Evening Dose	6 hours after midday dose	20 mg/kg

---

Preparation and Usage Rules

Translarna is supplied in single-dose sachets in strengths of 125 mg, 250 mg, and 1000 mg. Before ingestion, the entire contents of the granules must be mixed with a minimum of 30 ml of liquid (such as water or milk) or 3 tablespoons of soft food (such as yogurt or applesauce) to form a complete oral suspension.

If a dose is missed, a strict protocol determines whether it should be taken or skipped. For the morning or midday dose, it should be taken if the delay is less than three hours. For the evening dose, it should be taken if the delay is less than six hours. In all other cases, the dose must be skipped entirely, and the patient must not take a double dose to compensate.

Population Note: The 40 mg/kg/day regimen applies to patients aged two years and older with a body weight of 12 kg or more. No dosage adjustments are required for mild to moderate renal impairment or for any degree of hepatic impairment.

Research Evidence / Overview of Studies for Translarna

Evidence for Use in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Research for Translarna was studied for ambulatory males with Duchenne Muscular Dystrophy (DMD) linked to a specific nonsense mutation. The evidence is derived primarily from multiple randomized, double-blind, placebo-controlled trials (RCTs). These studies research examined how functional abilities, particularly walking, change over time in the observed populations. The study populations mainly included children and adolescents who were still able to walk.

The primary outcome that researchers used to measure functional change was the designated measure of the 6-Minute Walk Distance (6MWD). The major controlled trials reported that the findings were mixed on this primary endpoint when evaluating the overall patient groups. Specifically, some studies found that the 6MWD measurement in the overall treated population did not meet the pre-defined statistical threshold when compared against placebo.

However, subsequent analyses described patterns where secondary outcomes and results in certain patient groups were observed in some studies. For instance, studies monitored specific motor tasks, known as Timed Function Tests (TFTs), such as the time needed to climb stairs. These tests, along with certain composite functional measures, contribute to understanding symptom patterns related to functional capabilities in the observed patient groups.

---

Long-Term Studies and Registry Follow-up

Since nmDMD is a chronic condition, long-term effects are not fully established based only on the short-term RCTs. To address this, studies explored the long-term patterns through non-randomized observational registries. These registries tracked patients receiving the medicine over several years.

Data from these registry settings was observed in some studies to describe patterns related to the median age for the loss of ambulation (LoA) in the observed group compared to historical data sets of untreated patients. However, it is important to note that observational comparisons, like those with historical controls, carry a degree of uncertainty, as the patient groups may not be entirely comparable.

---

Consistency, Certainty, and Research Gaps

The evidence quality varies across studies, and the overall certainty remains low due to the key randomized trials not meeting their primary endpoint in the overall patient population. The primary limitation noted is the inconsistency in the primary outcome results across the two largest randomized trials. There is limited information for long-term outcomes that come from randomized, high-quality controlled settings. Research is ongoing to continue monitoring patients and build a more complete understanding of how symptoms evolved in the observed populations.

Common questions about Translarna (FAQ)

---

Q: What is the trade name (brand name) for the medicine containing the active ingredient ataluren?

A: The official product information confirms that the trade name (or brand name) for the medicine that contains the active ingredient ataluren is Translarna.

---

Q: What is the chemical name and structure of Ataluren?

A: According to regulatory sources and chemical databases, the active ingredient, ataluren, has the chemical name 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid. Its molecular formula is C15 H9 FN2 O3, which defines its specific structure and composition.

---

Q: How should Translarna granules be prepared for ingestion?

A: Regulatory guidelines indicate the contents of a single-dose sachet should be fully mixed with a minimum of 30 ml of liquid (such as water or milk) or with 3 tablespoons of soft food (like applesauce or yogurt). This mixing results in the oral suspension intended for administration.

---

Q: Is Translarna safe to use in patients who are pregnant or breastfeeding?

A: Regulatory documents recommend that the use of Translarna during pregnancy be avoided. Furthermore, official regulatory documents state that breastfeeding should be discontinued during treatment with this medicine.

---

Q: Are there any restrictions for using Translarna with food, alcohol, or herbal products?

A: Official regulatory documents specifically addressing drug interactions state that there are no restrictions documented for the concomitant use of Translarna with food, alcohol, or herbal products.

---

Q: Is there a body weight limit for the approved dosing regimen of Translarna?

A: Official labeling states the recommended regimen is indicated for patients with a body weight of 12 kg or more. Safety and effectiveness have not yet been established for patients who weigh less than 12 kg.

---

Q: What is the primary physical measurement used in clinical trials to evaluate the effect of Translarna on functional ability?

A: Studies and official information indicate that the primary functional outcome measure utilized in the major controlled clinical trials was the 6-Minute Walk Distance (6MWD). This is a designated measurement used in trials to track changes in walking ability.

---

Q: What is the consequence of the read-through action of ataluren on the muscle cell structure?

A: The mechanism of action aims to enable the cell's machinery to 'read through' the genetic stop signal, which promotes the synthesis of the full-length protein. The subsequent integration of this full-length protein is associated with the stabilization of the sarcolemma (the muscle cell membrane).

---

Q: How is the efficacy of Translarna tracked over the long term?

A: Long-term data regarding safety and effectiveness are primarily collected through post-authorization observational patient registries. These ongoing programs track treatment patterns and clinical outcomes in real-world settings to build a more complete understanding of long-term patterns.

---

Q: What happens if I accidentally take a double dose of Translarna?

A: The official product label strictly prohibits taking a double dose to compensate for a missed one. The potential for reduced effectiveness has been noted with increased dosing above the recommended daily amount.

How to Store and Dispose of Translarna (Ataluren) Granules

The storage and handling of Translarna granules must follow official regulatory guidelines to maintain product stability and ensure safety.

Storage Requirements

Product State	Temperature Limit	Container/Handling Rule
Unopened Sachets	Store below 30°C.	Keep in the original sealed, laminated foil sachets.
Prepared Dose (Mixed)	Room Temperature (15°C to 30°C)	Must be discarded if not consumed within 3 hours of preparation.
Prepared Dose (Mixed)	Refrigerated (2°C to 8°C)	Must be discarded if not consumed within 24 hours of preparation.

Disposal and Safety

The medicine must be stored out of the sight and reach of children. Any unused or expired Translarna granules or resulting waste material must be disposed of in accordance with local requirements. Medicines should not be disposed of via household wastewater or refuse.